Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
LUPIN ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
LUPIN Mar-23 |
ADCOCK INGRAM Jun-14 |
LUPIN/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 799 | 319 | - | |
Low | Rs | 583 | 230 | - | |
Sales per share (Unadj.) | Rs | 365.8 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 9.8 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 29.2 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Avg Dividend yield | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 270.7 | 74.5 | - | |
Shares outstanding (eoy) | m | 454.98 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.9 | 2.9 | 65.3% | |
Avg P/E ratio | x | 70.2 | -11.5 | -611.6% | |
P/CF ratio (eoy) | x | 23.7 | -13.9 | -170.8% | |
Price / Book Value ratio | x | 2.6 | 3.7 | 69.2% | |
Dividend payout | % | 40.7 | 0 | - | |
Avg Mkt Cap | Rs m | 314,381 | 46,340 | 678.4% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 30,872 | 2,908 | 1,061.5% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,417 | 16,016 | 1,039.1% | |
Other income | Rs m | 1,509 | 112 | 1,345.5% | |
Total revenues | Rs m | 167,926 | 16,128 | 1,041.2% | |
Gross profit | Rs m | 17,206 | -2,775 | -619.9% | |
Depreciation | Rs m | 8,807 | 691 | 1,274.1% | |
Interest | Rs m | 2,743 | 434 | 632.3% | |
Profit before tax | Rs m | 7,165 | -3,788 | -189.1% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,688 | 237 | 1,135.5% | |
Profit after tax | Rs m | 4,477 | -4,036 | -110.9% | |
Gross profit margin | % | 10.3 | -17.3 | -59.7% | |
Effective tax rate | % | 37.5 | -6.2 | -600.4% | |
Net profit margin | % | 2.7 | -25.2 | -10.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 124,513 | 11,730 | 1,061.5% | |
Current liabilities | Rs m | 92,654 | 6,600 | 1,403.8% | |
Net working cap to sales | % | 19.1 | 32.0 | 59.8% | |
Current ratio | x | 1.3 | 1.8 | 75.6% | |
Inventory Days | Days | 26 | 111 | 23.6% | |
Debtors Days | Days | 98 | 124 | 79.3% | |
Net fixed assets | Rs m | 103,490 | 6,838 | 1,513.5% | |
Share capital | Rs m | 910 | 74 | 1,223.8% | |
Net worth | Rs m | 123,156 | 12,571 | 979.7% | |
Long term debt | Rs m | 275 | 4,418 | 6.2% | |
Total assets | Rs m | 228,003 | 23,747 | 960.1% | |
Interest coverage | x | 3.6 | -7.7 | -46.7% | |
Debt to equity ratio | x | 0 | 0.4 | 0.6% | |
Sales to assets ratio | x | 0.7 | 0.7 | 108.2% | |
Return on assets | % | 3.2 | -15.2 | -20.9% | |
Return on equity | % | 3.6 | -32.1 | -11.3% | |
Return on capital | % | 8.0 | -19.8 | -40.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 18,972 | 1,367 | 1,387.8% | |
From Investments | Rs m | -12,868 | -420 | 3,065.5% | |
From Financial Activity | Rs m | -3,373 | 4,009 | -84.1% | |
Net Cashflow | Rs m | 2,732 | 4,957 | 55.1% |
Compare LUPIN With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare LUPIN With: KREBS BIOCHEMICALS ERIS LIFESCIENCES BDH INDUS. INNOVA CAPTAB LTD. NUTRAPLUS PR
Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.